In experimental schistosomiasis the degree of hepatic fibrosis often correlates with volume of hepatic granulomas, but there are numerous exceptions to this and the regulation of hepatic fibrosis and granuloma size are clearly at least partly independent.
It is clear that when comparing granuloma size and fibrosis that one should consider only those situations in which the duration of infection is the same in the groups being considered and in which only newly formed granulomas are measured, i.e. reactions around eggs containing mature, viable embryos.
It is less clear how one should quantify fibrosis. We have generally used the total increase above normal levels of hepatic collagen (determined as the increase in hydroxyproline per liver per egg). This gives a measure of the cumulative increase in total collagen (synthesis minus destruction) at any given time point, but different time points cannot be rigorously compared and rates of synthesis and destruction at specific times after infection are not determined. Collagen synthetic rates should give a better picture at any given moment, but one does not generally know the rate of collagen destruction at that moment. Even if the level of collagenases is known, should one in any case consider constitutive or latent collagenases, besides needing to consider at least type I and type III collagenases?
The frequent dissociation of granuloma size and collagen content or synthetic rates is evident in the lomas decrease in size and the collagen or synthetic rate per g granuloma does not change, i.e. the collagen or synthetic enzymes in the granulomas are perhaps decreased but compacted into a smaller volume ( Fig.) . However, when the granulomas remain the same size and the collagen and synthetic rates per g granuloma decrease or when different treatments have different effects , the results seem unequivocal. Similarly the results seem clearly interpretable when total hepatic collagen is considered in relation to egg numbers.
There are dissociations between granuloma size and fibrosis in addition to the treatments and comparisons noted in the Table. For example, in Schistosoma mansoni-infected mice granuloma volume does not change with intensity of infection (expressed as worm pairs or total liver eggs) while the fibrosis per egg decreases as infection intensity increases (Cheever 1986) .
We know nothing of the kinetics of collagen deposition in relation to granuloma size in humans. We do know that in many cases of "active" Symmers' fibrosis that downregulatory antiidiotypic T cells are absent and proliferation of peripheral blood mononuclear cells is greater than that in asymptomatic hepato-intestinal cases (Montesano et al. 1990) . Similar anti-idiotypic T cells downregulate the size of in vitro granulomas formed around schistosome eggs by PMBC of infected patients (Parra et al. 1991) . Obviously, it will be important to have surrogate variables of hepatic fibrosis and collagenolysis to follow in infected humans. Past studies suggest that serum procollagen III (Zwingenberger et al. 1988 , Mincis et al. 1990 , Fayol et al 1991 , Shahin et al. 1992 or other serum precursors (Tanabe et al. 1989 , Parise & Rosa 1992 , Shahin et al. 1995 or in vitro responses of liver from infected patients (Dunn et al. 1979 , Monteiro & Borojevic 1995 may be of interest in this regard. Collagen production by in vitro granulomas (Parra et al. 1991) 
cells (S. mansoni and S. japonicum).
Immunoregulation of schistosomal hepatic fibrosis has been less examined and might affect pathways involved in collagen synthesis, cross-linking or collagenase activity. All of these pathways determining granuloma size and fibrosis are presumably affected by the balance of cytokines which may affect reaction size and fibrosis in different ways or to different degrees. For example, cytokines affecting cell recruitment might be expected to affect primarily the size of granulomas. Some treatments noted in the Table, i.e. anti-IL-4 treatment (Cheever et al. 1994) , may act directly on enzymes affecting collagen (Postlewaite et al. 1992) as well as through immunoregulatory pathways.
